• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Grants New Indication For Pfizer/Bristol Anticoagulant
The FDA has approved a new indication for apixaban (Eliquis), the anticoagulant drug manufactured by Bristol-Myers Squibb and Pfizer. The new indication is for the prophylaxis of deep vein thrombosis (DVT) in patients who have undergone hip or knee replacement surgery. DVT can lead to the life-threatening condition of pulmonary embolism (PE). The DVT prophylaxis indication joins the previously approved indication of stroke prevention in patients who have nonvalvular atrial fibrillation.
Source: Forbes.com Healthcare News - March 14, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

025 * ablative maze surgery normalizes left ventricular function in patients with lone atrial fibrillation
Conclusions: Within a dedicated AF centre, ablative maze surgery grants excellent outcomes, with symptom relief and negligible risk. It provides a complete reversal of AF-related myocardial dysfunction and is therefore a convenient alternative to His bundle ablation and lifelong pacemaker dependency in symptomatic refractory patients.
Source: Interactive CardioVascular and Thoracic Surgery - September 18, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Pozzoli, A., Taramasso, M., Coppola, G., Kamami, M., La Canna, G., Della Bella, P., Alfieri, O., Benussi, S. Tags: Arrhythmia I Source Type: research

Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting
Patients with atrial fibrillation affected by an acute coronary syndrome have indications for oral anticoagulation and dual antiplatelet therapy with aspirin and a P2Y12 adenosine diphosphate receptor inhibitor after coronary artery stenting. The concurrent use of all 3 agents, termed triple oral antithrombotic therapy, significantly increases the risk of bleeding. To date, there is a lack of evidence on the proper combination and duration of anticoagulant and antiplatelet agents in patients with indications for both therapies. As such, care has been guided by expert opinion, and there is wide variation in clinician practi...
Source: Clinical Cardiology - July 1, 2013 Category: Cardiology Authors: Grant W. Reed, Christopher P. Cannon Tags: Review Source Type: research

Missed Opportunities for Appropriate Anticoagulation Among Emergency Department Patients With Uncomplicated Atrial Fibrillation or Flutter
Conclusion: In this cohort of ED patients with uncomplicated atrial fibrillation or flutter who were discharged without cardiology involvement, many were not appropriately anticoagulated before ED arrival, and more than half of such patients did not appear to have corrective measures initiated by the emergency physician. This may represent a potential opportunity to improve patient care and outcomes.
Source: Annals of Emergency Medicine - May 28, 2013 Category: Emergency Medicine Authors: Frank X. Scheuermeyer, Grant Innes, Reza Pourvali, Chris Dewitt, Eric Grafstein, Claire Heslop, Jan MacPhee, John Ward, Brett Heilbron, Lorraine McGrath, Jim Christenson Tags: Cardiology Source Type: research

UCLA brain-imaging tool and stroke risk test help identify cognitive decline early
UCLA researchers have used a brain-imaging tool and stroke risk assessment to identify signs of cognitive decline early on in individuals who don't yet show symptoms of dementia.   The connection between stroke risk and cognitive decline has been well established by previous research. Individuals with higher stroke risk, as measured by factors like high blood pressure, have traditionally performed worse on tests of memory, attention and abstract reasoning.   The current small study demonstrated that not only stroke risk, but also the burden of plaques and tangles, as measured by a UCLA brain scan, may influence c...
Source: UCLA Newsroom: Health Sciences - April 3, 2013 Category: Universities & Medical Training Source Type: news

Predictors of Good Clinical Outcome in Acute Stroke Patients Underwent Recanalization Therapy (P01.242)
CONCLUSIONS: NIHSS at admission, recanalization grade and early neurological improvement are independent predictors of clinical outcome in AIS patients underwent mechanical recanalization.Supported by: IGA MH CR grants NT/11386-5/2010, NT/11046-6/2010, NT/13498-4/2012.Disclosure: Dr. Skoloudik has nothing to disclose. Dr. Roubec has nothing to disclose. Dr. Kuliha has nothing to disclose. Dr. Herzig has received personal compensation for activities with Bayer, Boehringer Ingelheim Pharmaceuticals, Inc., and Gedeon Richter. Dr. Sanak has received personal compensation from Boehringer Ingelheim for serving on a scientific ad...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Skoloudik, D., Roubec, M., Kuliha, M., Herzig, R., Sanak, D., Prochazka, V., Hrbac, T. Tags: P01 Cerebrovascular Disease I Source Type: research

Novel Oral Anticoagulants in Atrial Fibrillation: A Meta‐analysis of Large, Randomized, Controlled Trials vs Warfarin
Conclusions:Novel oral anticoagulants may be superior to warfarin in patients with atrial fibrillation, reducing the composite of stroke or systemic embolism and lowering all‐cause mortality. The benefit is largely due to fewer hemorrhagic strokes.Ernesto Paolasso, MD, is a national lead investigator for a clinical trial sponsored by Daiichi‐Sankyo investigating a novel oral anticoagulant. Robert Giugliano, MD, SM, is a member of the TIMI Study Group, which has received research grant support from Johnson & Johnson and from Daiichi‐Sankyo related to clinical trials of anticoagulants. Dr. Giugliano has received ho...
Source: Clinical Cardiology - January 1, 2013 Category: Cardiology Authors: Ariel Dogliotti, Ernesto Paolasso, Robert P. Giugliano Tags: Review Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12